Xvivo Perfusion AB (publ) (0RKL.L) LSE

Currency In SEK

AD

Valuation

Market Cap5.82B
Enterprise Value5.76B
P/E Ratio79
PEG Ratio-3.83
Price/Sales Ratio7.81
Price/Book Ratio3.18
Enterprise/Revenue7.61
Enterprise/EBITDA36.98

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.1
Operating Margin0.13
AD

Management Effectiveness

Return On Assets0.04
Return On Equity0.04

Income Statement

Revenue812.17M
Revenue/Share28.42
Gross Profit533.5M
EBITDA153.14M
Net Income25.16M
Diluted EPS0.8

Balance Sheet

Total Cash304.96M
Total Cash/Share9.68
Total Debt121.62M
Total Debt/Equity0.06
Current Ratio3.86
Book Value Per Share69.85

Price History

52-Week Change33.02
52-Week High343.52
52-Week Low160.8
Moving Average 50 Days291.55
Moving Average 200 Days282.98

Statistics

Average Volume9,843
Shares Outstanding31.5M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD